Introduction. The inhibition of angiotensinconverting enzyme could be useful to avoid sarcopenia in the elderly. Materials and methods. We compared in a prospective double blind trial, the effects of treatment with enalapril or nifedipine on muscle performance in hypertensive elderly subjects. Patients were followed for nine months, and at baseline, 4.5 months and the end of follow-up, quadriceps and hand grip muscle strength, walking capacity, timed up and go and the short physical performance test were measured. Results. During follow-up, more subjects on nifedipine than on enalapril discontinued the medication due to side-effects. No differences in the evolution of muscle strength, walking capacity or functional measures were observed. At nine months, plasma angiotensin-converting enzyme activity decreased by 6.0±2.5 U/L among patients on enalapril and increased by 8.5±4.2 U/L (p<0.001) among patients on nifedipine. Conclusion. In this group of elderly subjects, enalapril was not superior to nifedipine with regard to the age-related decline of muscle performance.
Introduction
Sarcopenia (loss of skeletal muscle mass) is an important cause of physical disability among the elderly. 1 We have shown that there is a mean loss of 230 and 500 g/year of fat free mass among healthy women and men older than 70 years, respectively. 2 The only therapeutic intervention that reduces the functional consequences of sarcopenia is resistance training, but it is limited by the high attrition rates and low long-term compliance with training programmes. 3 Therefore, the search for other strategies to prevent or reverse sarcopenia seems worthwhile.
Subjects receiving angiotensin-converting enzyme (ACE) inhibitors for cardiac failure have lower mortality and disability rates. 4 Although there is a clear cut effect of these drugs on cardiac remodelling and such an action may explain their beneficial effects, there is also evidence that these drugs may improve muscle mass and strength. 5 Therefore, it is possible that angiotensin may promote muscle loss and that its inhibition may avoid this deleterious effect. There are genetic studies showing that people bearing the II genotype of ACE have a lower metabolic activity of the enzyme, and better anabolic response after an intensive aerobic training programme, as compared with bearers of the DD genotype, which is associated with a higher ACE activity. 6 Other studies have shown that the ID genotype is associated with higher abdominal fat accretion in men. 7 However, there are also clinical studies that have failed to show a beneficial effect of ACE inhibitors on muscle strength and have only demonstrated that those subjects using these medications lose more weight. 8 The possible deleterious effects of ACE on muscle may be mediated by an inhibition of insulin-like growth factor action in muscle that would promote ubiquinone-mediated proteolysis and muscle cell apoptosis. 9 There is also evidence that ACE stimulates the expression of nuclear factor κB, and hence inflammatory mediators such as interleukin-6 10 and tumour necrosis factor α 11 in muscle tissue. Finally, the proteolytic degradation of bradykinin, a modulator of insulin action in muscle and fat, is also blocked by ACE inhibition. 12 Therefore, the aim of this study was to compare in a double blind fashion, the effects of an ACE inhibitor with a calcium channel blocker on 
Materials and methods
Community living elderly subjects aged 70 years or more, with stage I hypertension under treatment defined according to the Seventh Joint National Committee (JNC 7), 13 were considered eligible for the study if they were able to reach the clinic by their own means, did not have cardiac or liver failure, had a glomerular filtration rate over 60 ml/h/1.73 m 2 , calculated according to serum creatinine levels, were not taking betablockers, did not have diabetes mellitus diagnosed more than five years ago, did not have dementia, defined as a mini mental score of less than 20, 14 and did not have a history of adverse effects to ACE inhibitors.
All subjects were subjected to a baseline assessment that included a medical examination and drawing of a blood sample for routine laboratory assessment, measurement of ACE polymorphism and plasma ACE activity. They were also subjected to the following measurements:
1. Body composition measurement by double beam X-ray absorptiometry in Lunar Prodigy Equipment (General Electric Medical Systems, Madison, WI, USA).
Quadriceps strength using a quadriceps table
and a digital force transducer, as previously described, 15 and hand grip strength using a hand grip dynamometer (Therapeutic Instruments, Clifton, NJ, USA). Both measurements were expressed as 1RM in kg. 3. Endurance, measured as the distance that subjects could walk at a constant pace on a flat surface during 12 minutes. 16 4. General physical fitness, measuring the timed up and go (TUG), expressed in seconds (better performance at lower time required), 17 and the short physical performance battery (SPPB), expressed as a score (better performance at higher scores). 18 Subjects were randomised using a random number generator and programme developed in Fox Pro ® and matched for gender, age and body mass index to receive enalapril at an initial dose of 10 mg/day or nifedipine slow-release tablets at an initial dose of 20 mg/day. No washout period was used. Medications were delivered in identical bottles and tablets, identified only by a numeric code. Patients were also advised to modify their diets according to the Dietary Approaches to Stop Hypertension (DASH) principles. They were evaluated two weeks after starting treatment and if blood pressure exceeded 140 mmHg (systolic) or 90 mmHg (diastolic), the dose of medication was doubled. Two weeks later, if target blood pressure values were not achieved, a diuretic (hydrochlorothiazide) was added to the treatment.
Thereafter, subjects were evaluated monthly. At each visit, they were asked about adverse events, falls and dizziness. Blood pressure was measured and a new bottle of medications was delivered. The unused pills returned were counted to assess compliance. If a subject requested to stop the study medication due to adverse effects, he/she was advised to return to his/her original medications but to continue the follow-up and assessments. Codes were not broken in these cases. In case of serious adverse effects, medication codes were broken by an external professional and those in charge of patients remained unaware of the medication used. Routine laboratory assessments were performed using automated techniques in a clinical laboratory (Vida Integra). ACE polymorphism was determined by quantitative PCR using the technique described by Lindpaintner et al. 19 Plasma ACE activity was measured using a colourimetric method described by Neels et al. 20 Statistical analysis was done in Stata 8 for Windows (Stata Corporation, Texas, USA). Variables with a normal distribution were expressed as mean± standard deviation. The evolution of outcomes was evaluated using analysis of variance for repeated measures, using gender, ACE polymorphism and ACE activity as covariants. Differences between means were assessed using students t test. Differences between proportions were analysed using Fisher's exact test. Fall free survival was analysed using life tables, considering the first fall reported as the ending event in fall free survival. All analyses were done according to intention to treat (including all subjects that concluded the follow-up) and per protocol (including only subjects that continued with the study medication in a double blind fashion). 
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The study was approved by INTA's ethics committee and all subjects signed written informed consent.
Results
We screened 150 hypertensive elderly subjects and 120 were admitted to the study. Prior to the study, 84 patients were treated with enalapril, 20 with nifedipine, four with hydrochlorothiazide, one with amlodipine, three with nitrendipine, one with losartan and seven were not receiving medications. Patient flow is depicted on figure 1. Forty patients originally taking enalapril were switched to nifedipine and 16 patients originally taking calcium channel blockers were switched to enalapril. The proportion of subjects that discontinued medications due to adverse effects was significantly higher among patients taking nifedipine (Fisher p<0.01). Initial demographic and laboratory data of subjects are shown in table 1. No significant differences in these parameters were observed between subjects randomised to enalapril or nifedipine.
Enalapril group (60 subjects)
9 subjects discontinued the study drug, due to adverse effects and returned to their usual antihypertensive medication, but continued the follow up 15 subjects had concomitant diseases, 3 had a history of adverse effects to study medications, 3 had a low minimental score and 9 refused to sign the informed consent 150 community living hypertensive patients were screened 120 were randomized matching by age sex and body mass index to receive enalapril or nifedipine in a double blind fashion Table 1 Baseline data of studied patients. According to leftover pill count, the compliance with medication was 63.1±28.9 and 76.2±26.5% among patients on nifedipine and enalapril, respectively (p<0.01).
On a per protocol analysis, no differences in the evolution of muscle strength, functional capacity and body composition were observed between the two treatment groups (table 2) . The results did not change when both genders were analysed separately or on intention to treat analysis (table 3) . If results were analysed calculating the change from baseline in strength and functional parameters, still no differences between treatment groups were detected. Fall free survival was not different between groups either (figure 2).
Of the 84 patients receiving enalapril prior to the study, 40 were switched to nifedipine and 44 continued with the same medication after randomisation. In a subgroup analysis comparing the 40 patients that were switched to nifedipine and the 44 that continued with enalapril, no differences in the evolution of muscle strength or functional measures were observed.
Sixteen patients (10 in the enalapril group and six in the nifedipine group) received thiazide diuretics during the trial. If these patients were excluded from the analysis, the results did not change.
With respect to ACE polymorphism, eight patients were homozygotes for DD genotype, 91 were heterozygotes (ID) and 21 were homozygotes for II genotype. The proportion of subjects with different genotypes was homogeneous between groups. Baseline plasma ACE activity was 26.9±26.5, 17.9±22.2 and 7.4±12.5 U/L in groups DD, ID and II, respectively (ANOVA p=0.05). Among the groups receiving nifedipine and enalapril, basal ACE activity was 18.0±25.7 and 16.0±16.8 U/L, respectively (p value non-significant). There was no association between ACE genotype and muscle strength or functional capacity at baseline.
At the end of the follow-up period, ACE activity decreased by 6.0±2.5 U/L among patients on enalapril and increased by 8.5±4.2 U/L (p<0.001) among patients on nifedipine. Performing an intention to treat or per protocol analysis, there was no association between the change in ACE activity during follow-up and changes in muscle strength or functional capacity. If ACE activity was introduced as a covariate in the repeated measures analysis, results did not change substantially.
Discussion
In this study performed in hypertensive elderly subjects living in the community, we did not observe a beneficial effect of enalapril on muscle strength or functional capacity when compared with nifedipine.
We used nifedipine as the comparator drug since the use of diuretics could cause electrolyte disturbances that could affect muscle performance, 21 our main outcome measure. On the other hand, the use of placebo as comparison could have been an alternative, considering that there are doubts about the real benefits of antihypertensive medications in the elderly. However, a recent study confirmed our impression that, even in octogenarians, lowering blood pressure is associated with a significant reduction in mortality and morbidity. 22 Subjects treated with nifedipine had a higher frequency of side-effects and a higher rate of drug discontinuation than those treated with enalapril, an issue that is a weakness of this study. It is known that ACE inhibitors are often associated with a better quality of life among hypertensive elderly subjects. 23 The lack of effect of enalapril on muscle performance is in contradiction with a recent trial that compared perindopril with placebo in the elderly 24 and observed a positive effect of the drug on walking capacity. However, that study was performed in normotensive patients with some 25 or no effects 26 of ACE inhibitors on muscle function. We are confident that our results are not flawed since the study was adequately powered to detect a difference of 10% in walking capacity with a power of 0.8, even considering the 31 subjects that discontinued the medication. Moreover, we employed two control measures to assess compliance with medication. First, counting leftover pills confirmed that at least 60% of the prescribed dose was actually taken by patients. Secondly, the significant reduction in ACE activity in patients taking enalapril and the striking difference in ACE activity in those taking nifedipine gives a biochemical confirmation of the pharmacological action. Eightyeight percent of participants were already receiving either ACE inhibitors or calcium channel blockers at the initiation of the study. Therefore, we cannot dismiss entirely a residual effect of these medications on the results obtained.
In previous studies, we have used resistance training to boost the beneficial effects of experimental treatments on muscle strength. Earlier studies by other groups have shown that the effects of ACE activity on muscle can become evident when evaluating the response to training. 27 However, this strategy further fragments treatment groups, decreasing the power of the study and we have not observed interactions between training and other interventions in boosting muscle strength. 28 Therefore, in this study we opted for the strategy of a single intervention.
The lack of effect on falls is not surprising. Although good muscle function is essential to maintain a standing position, falls have multifactorial causes 29 and cannot be considered as a main outcome of this study. This is especially true, considering that strategies directed only to improve muscle strength and not to modify balance have been reported to have no effect on falls. 30 
Conclusion
In this group of elderly subjects, enalapril was not superior to nifedipine in modifying the agerelated decline of muscle performance. 
